Search | Clinical Trials Finder

Conditions: Pain
Interventions: Suzetrigine, DRSP/EE, NGM/EE; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: TRV130, Moxifloxacin, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Post Cataract Surgery
Interventions: Triamcinolone (Optional), control group; Drug
Lead sponsor: Research Insight LLC; Industry
Eligibility: 22 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Community-acquired Bacterial Pneumonia
Interventions: Solithromycin, Moxifloxacin, Placebo to match solithromycin; Drug · Other
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 25
States / cities: Glendale, California • Los Angeles, California • Mission Hills, California + 18 more

Conditions: Bacterial Infections, Eye Infections
Interventions: AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution); Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Acne Vulgaris
Interventions: SB204 4%, SB204 8% or 12%, Vehicle; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Community-acquired Pneumonia, Influenza, COVID-19
Interventions: Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir; Drug · Other · Biological + 1 more
Lead sponsor: UMC Utrecht; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 11
States / cities: Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more

Conditions: Healthy
Interventions: ALXN1840, Placebo, Moxifloxacin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: CHF5993, CHF5259, Moxifloxacin 400mg, CHF5993 Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: mipomersen sodium, moxifloxacin hydrochloride (Avelox®), placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions: Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2); Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Dexpramipexole, Dexpramipexole Placebo, Moxifloxacin; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Solid Tumors
Interventions: AZD6094 200 mg, Placebo, Moxifloxacin; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bronchitis, Sinusitis, Urinary Tract Infections
Interventions: Fluoroquinolone (FQ), Azithromycin (AZ), Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 239,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Hepatitis C Virus
Interventions: Ortho Tri-Cyclen®, BMS-650032; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: Selpercatinib, Moxifloxacin, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Tuberculosis
Interventions: SQ109, SQ109 Placebo, Moxifloxacin; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pediatric ALL
Interventions: Standard of care drug; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Rivipansel; Drug
Lead sponsor: GlycoMimetics Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Endometriosis, Unexplained Infertility
Interventions: Elagolix, Ortho Cyclen; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2409021, Placebo, Moxifloxacin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteers
Interventions: ACP-196, Moxifloxacin 400 mg, Placebo; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Bacterial Infections, Eye Infections, Cataract Extraction
Interventions: AzaSite Eye Drops, Vigamox Eye Drops; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 21 Years and older
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 13
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Mission Hills, California + 10 more

Conditions: Epithelium, Corneal
Interventions: Moxifloxacin, Gatifloxacin; Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)

Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

Electrophysiological Effects of Potential QT Prolonging Drugs

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

Fluoroquinolone Associated Disability

Drug Interaction Oral Contraceptive Pill (OCP)

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

Effects of SQ109 on QTc Interval in Healthy Subjects

Pharmacokinetics of Drugs Administered to Children

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

Elagolix for Fertility Enhancement Clinical Trial

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)